2022年碘对比剂短缺期间MRA作为肺栓塞首选检查:单中心经验
本研究回顾性分析2019、2021和2022年4月1日至7月31日单中心为排除肺栓塞行CTA和MRA的检查。2022年短缺期间MRA作为首选检查,MRA检查量增加,估计4个月节省27 L碘海醇(350 mg I/mL),MRA图像质量受限比例低于CTA(10.3% vs 13.9%)。
要点
- 2022年短缺期间MRA作为肺栓塞首选检查,第8-11周MRA检查量超过CTA。
- 2022年MRA图像质量受限比例为10.3%,低于CTA的13.9%。
- MRA阴性后2周内行CTA的7例患者,CTA均为阴性。
核心结论
- 在2022年碘对比剂短缺期间,对普通人群首选肺MRA诊断肺栓塞有助于节约碘对比剂。
研究设计与样本
- 回顾性单中心研究,纳入2019、2021和2022年4月1日至7月31日(18个周期间)为排除肺栓塞行CTA和MRA的全部检查,共4491次检查(4006例患者),参考标准为CTA和MRA报告。
诊断标准与关键数值
- 2022年CTA图像质量受限比例为13.9%,MRA为10.3%。
- 2022年MRA阴性后2周内行CTA的7例患者,CTA均为阴性。
临床应用与阅片要点
- 2022年5月初至7月中旬,该机构将MRA作为肺栓塞诊断的首选检查以节约碘对比剂。
- 2022年第1周MRA检查量为4次(按7天周期归一化为9次),第10周增至最多63次,第18周降至10次。
- 2022年第8-11周,MRA检查量(范围45-63次)多于CTA检查量(范围27-46次)。
- 2022年首选MRA使4个月估计节省27 L碘海醇(350 mg I/mL),该估计基于CTA使用量每年均匀简单线性增长的假设和CTA剂量1 mL/kg。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Closure of a GE Healthcare facility in Shanghai, China, in 2022 disrupted the iodinated contrast media supply. Technologic advances have addressed limitations associated with the use of pulmonary MRA for diagnosis of pulmonary embolism (PE). OBJECTIVE. The purpose of this study was to describe a single institution's experience in the use of pulmonary MRA as an alternative to CTA for the diagnosis of PE in the general population during the iodinated contrast media shortage in 2022. METHODS. This retrospective single-center study included all CTA and MRA examinations performed to exclude PE from April 1 through July 31 (18 weekly periods) in 2019 (before the COVID-19 pandemic and contrast media shortage), 2021 (during the pandemic but before the shortage), and 2022 (during both the pandemic and the shortage). From early May through mid-July of 2022, MRA served as the preferred test for PE diagnosis, to preserve iodinated contrast media. CTA and MRA reports were reviewed. The total savings in iodinated contrast media volume resulting from preferred use of MRA was estimated. RESULTS. The study included 4491 examinations of 4006 patients (mean age, 57 ± 18 [SD] years; 1715 men, 2291 women): 1245 examinations (1111 CTA, 134 MRA) in 2019, 1547 examinations (1403 CTA, 144 MRA) in 2021, and 1699 examinations (1282 CTA, 417 MRA) in 2022. In 2022, the number of MRA examinations was four (nine when normalized to a 7-day period) in week 1, and this number increased to a maximum of 63 in week 10 and then decreased to 10 in week 18. During weeks 8-11, more MRA examinations (range, 45-63 examinations) than CTA examinations (range, 27-46 examinations) were performed. In 2022, seven patients with negative MRA underwent subsequent CTA within 2 weeks; CTA was negative in all cases. In 2022, 13.9% of CTA examinations (vs 10.3% of MRA examinations) were reported as having limited image quality. The estimated 4-month savings resulting from preferred use of MRA in 2022, under the assumption of uniform simple linear growth in CTA utilization annually and a CTA dose of 1 mL/kg, was 27 L of iohexol (350 mg I/mL). CONCLUSION. Preferred use of pulmonary MRA for PE diagnosis in the general population helped to conserve iodinated contrast media during the 2022 shortage. CLINICAL IMPACT. This single-center experience shows pulmonary MRA to be a practical substitute for pulmonary CTA in emergency settings.
引用
- Starekova, Chu, Bluemke, et al. MRA as the Preferred Test for Pulmonary Embolism During the Iodinated Contrast Media Shortage of 2022: A Single-Center Experience. AJR Am J Roentgenol. 2023. PMID: 37341181. doi:10.2214/AJR.23.29340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。